Avadel Pharmaceuticals plc Announces Form 8.3 Regulatory Disclosure

On 6 February 2026, Avadel Pharmaceuticals plc published a regulatory disclosure under Rule 8.3 of the Irish Takeover Panel Act, 1997 and the Takeover Rules, 2013. This Form 8.3 filing outlines dealings by a major investor holding over 1% of the company’s ordinary shares and provides information on purchases of shares in the company by that investor.

Overview of Regulatory Filing

The disclosure was submitted through State Street International (Ireland) Limited in accordance with the requirements of the Irish Takeover Panel. The purpose of the filing is to report dealings in relevant securities — specifically ordinary shares — by a person or entity representing 1% or more of the company’s share capital.

Details of Share Dealings

The Form 8.3 report identifies State Street Global Advisors & Affiliates as the reporting party engaged in dealings of Avadel Pharmaceuticals plc ordinary shares. The class of securities involved in the disclosure are the company’s $0.01 ordinary shares.

The investor’s interest and positions following the dealings are:

• Relevant securities: 2,363,090 shares
• Percentage of total share capital: 2.42609%

These figures represent the holdings of the reporting investor after completing share purchases on 5 February 2026.

Purchases Made by the Investor

The Form 8.3 report breaks down the specific transactions completed by the investor on the 5th of February. The following purchases were disclosed:

• 7,302 shares purchased at a price of 21.60 per unit
• 896 shares purchased at a price of 21.60 per unit
• 896 shares purchased at a price of 21.60 per unit

These transactions were executed as part of the investor’s ongoing accumulation of Avadel Pharmaceuticals plc shares.

No Derivatives or Options Transactions Reported

The filing confirms that there were no reported dealings involving derivatives, options, or other agreements to purchase or sell additional securities related to Avadel Pharmaceuticals plc. This includes:

• Derivatives transactions (such as CFDs or futures) – None
• Options transactions (including writing or exercising options) – None

There were also no other types of transactions reported, such as new securities issuance or rights offerings.

Other Relevant Information

The disclosure confirms that there are no supplemental Form 8 attachments accompanying this filing. It also states that there are no agreements, arrangements, or understandings in place relating to voting control, options, or derivative-based acquisition of shares.

Regulatory Contact and Filing Information

The disclosure was formally submitted on 6 February 2026 and includes contact details for regulatory communication as part of the Irish Takeover Panel requirements. The contact person listed in the filing is Divya K, with a listed telephone number associated with the submission.

This regulatory update ensures transparency in share ownership and trading activity by significant investors in Avadel Pharmaceuticals plc, in compliance with Irish market regulations.

#AvadelPharmaceuticals #Form83 #IrishTakeoverPanel #StateStreetInvestors #SlimScan #GrowthStocks #CANSLIM